These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 30543573

  • 1. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, Mouzas I, Koutroubakis IE.
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [Abstract] [Full Text] [Related]

  • 2. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Löwenberg M, Benninga MA, D'Haens GR, Kindermann A.
    Scand J Gastroenterol; 2015 Feb; 50(9):1110-7. PubMed ID: 25865965
    [Abstract] [Full Text] [Related]

  • 3. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
    Choi SY, Kang B, Choe YH.
    Gut Liver; 2019 Sep 15; 13(5):541-548. PubMed ID: 30970435
    [Abstract] [Full Text] [Related]

  • 4. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L, Kolho KL.
    J Pediatr Gastroenterol Nutr; 2017 Feb 15; 64(2):272-278. PubMed ID: 27149256
    [Abstract] [Full Text] [Related]

  • 5. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.
    J Pediatr Gastroenterol Nutr; 2019 Jun 15; 68(6):847-853. PubMed ID: 30633108
    [Abstract] [Full Text] [Related]

  • 6. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.
    Gastroenterology; 2015 Jun 15; 148(7):1320-9.e3. PubMed ID: 25724455
    [Abstract] [Full Text] [Related]

  • 7. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A, Batovsky M, Gregus M, Hlista M, Durina J, Leskova Z, Sturdik I, Gojdic M, Jalali Y, Koller T, Toth J, Huorka M, Hlavaty T.
    Acta Gastroenterol Belg; 2018 Jun 15; 81(4):465-470. PubMed ID: 30645913
    [Abstract] [Full Text] [Related]

  • 8. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
    Roblin X, Nancey S, Papamichael K, Duru G, Flamand M, Kwiatek S, Cheifetz A, Fabien N, Barrau M, Paul S.
    J Crohns Colitis; 2024 May 31; 18(5):679-685. PubMed ID: 37934041
    [Abstract] [Full Text] [Related]

  • 9. Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations.
    Ferreira AI, Lima Capela T, Arieira C, Xavier S, Cotter J.
    Eur J Gastroenterol Hepatol; 2024 Nov 01; 36(11):1314-1318. PubMed ID: 39166409
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-Horin S, Weiss B.
    J Pediatr Gastroenterol Nutr; 2018 Oct 01; 67(4):507-512. PubMed ID: 29901557
    [Abstract] [Full Text] [Related]

  • 12. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.
    J Crohns Colitis; 2018 Nov 15; 12(11):1316-1325. PubMed ID: 30239644
    [Abstract] [Full Text] [Related]

  • 13. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
    Dave MB, Dherai AJ, Desai DC, Mould DR, Ashavaid TF.
    Eur J Clin Pharmacol; 2021 Jan 15; 77(1):55-62. PubMed ID: 32803288
    [Abstract] [Full Text] [Related]

  • 14. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
    Naviglio S, Lacorte D, Lucafò M, Cifù A, Favretto D, Cuzzoni E, Silvestri T, Pozzi Mucelli M, Radillo O, Decorti G, Fabris M, Bramuzzo M, Taddio A, Stocco G, Alvisi P, Ventura A, Martelossi S.
    J Pediatr Gastroenterol Nutr; 2019 Jan 15; 68(1):37-44. PubMed ID: 30211845
    [Abstract] [Full Text] [Related]

  • 15. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.
    Nemoz B, Ternant D, Bailly S, Gautier-Veyret E, Jourdil JF, Bonaz B, Stanke-Labesque F.
    Br J Clin Pharmacol; 2019 Apr 15; 85(4):722-728. PubMed ID: 30575085
    [Abstract] [Full Text] [Related]

  • 16. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
    Teixeira FV, Sassaki LY, Saad-Hossne R, Baima JP, Magro DO, Coy CSR, Kotze PG.
    Arq Gastroenterol; 2018 Apr 15; 55(2):192-197. PubMed ID: 30043873
    [Abstract] [Full Text] [Related]

  • 17. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH.
    World J Gastroenterol; 2017 Feb 28; 23(8):1489-1496. PubMed ID: 28293096
    [Abstract] [Full Text] [Related]

  • 18. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S.
    J Crohns Colitis; 2015 Jul 28; 9(7):525-31. PubMed ID: 25895875
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL.
    Eur J Gastroenterol Hepatol; 2018 Jul 28; 30(7):699-703. PubMed ID: 29538037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.